pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2010-6-109-119pulmo-1726Research ArticleОБЗОРЫREVIEWИнгаляционные глюкокортикостероиды при хронической обструктивной болезни легкихАвдеевС. Н.serg_avdeev@list.ruФГУ "НИИ пульмонологии" ФМБА РоссииRussian Federation20102812201006109119Copyright © Авдеев С.Н., 20102010Авдеев С.Н.Авдеев С.Н.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/1726хроническая обструктивная болезнь легкихингаляционные глюкокортикостероидыкомбинированные препаратыReferencesGlobal initiative for chronic obstructive lung disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. Last updated 2009Global initiative for chronic obstructive lung disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. Last updated 2009www.goldcopd.orgwww.goldcopd.orgCelli B.R., MacNee W. ATS / ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS / ERS position paper. Eur. Respir. J. 2004; 23: 932-946Celli B.R., MacNee W. ATS / ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS / ERS position paper. Eur. Respir. J. 2004; 23: 932-946Buist A.S., McBurnie M.A., Vollmer W.M. et al. Inter� national variation in the prevalence of COPD (the BOLD Study): a population�based prevalence study. Lancet 2007; 370: 741-750Buist A.S., McBurnie M.A., Vollmer W.M. et al. Inter� national variation in the prevalence of COPD (the BOLD Study): a population�based prevalence study. Lancet 2007; 370: 741-750Mannino D.M., Homa D.M., Akinbami L.J. et al. Chronic obstructive pulmonary disease surveillance - United States, 1971-2000. Morbid. Mortal. Wkly Rep. Surveill Summ. 2002; 51: 1-16Mannino D.M., Homa D.M., Akinbami L.J. et al. Chronic obstructive pulmonary disease surveillance - United States, 1971-2000. Morbid. Mortal. Wkly Rep. Surveill Summ. 2002; 51: 1-16Murray C.J., Lopez A.D. Alternative projections of mortal� ity and disability by cause 1990-2020: Global burden of disease study. Lancet 1997; 349: 1498-1504Murray C.J., Lopez A.D. Alternative projections of mortal� ity and disability by cause 1990-2020: Global burden of disease study. Lancet 1997; 349: 1498-1504Wise R.A., Tashkin D.P. Optimizing treatment of chronic obstructive pulmonary disease: An assessment of current therapies. Am. J. Med. 2007; 120: 4-13Wise R.A., Tashkin D.P. Optimizing treatment of chronic obstructive pulmonary disease: An assessment of current therapies. Am. J. Med. 2007; 120: 4-13Celli B.R. Update on the management of COPD. Chest 2008; 133: 1451-1462Celli B.R. Update on the management of COPD. Chest 2008; 133: 1451-1462Tashkin D.P., Celli B., Senn S. et al. for the UPLIFT Study Investigators. A 4�year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359: 1543-1554Tashkin D.P., Celli B., Senn S. et al. for the UPLIFT Study Investigators. A 4�year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359: 1543-1554Decramer M., Celli B., Kesten S. et al. for the UPLIFT investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a ran� domised controlled trial. Lancet 2009; 374: 1171-1178Decramer M., Celli B., Kesten S. et al. for the UPLIFT investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a ran� domised controlled trial. Lancet 2009; 374: 1171-1178Rennard S.I., Anderson W., ZuWallack R. et al. Use of a long�acting inhaled β2�adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 163: 1087-1092Rennard S.I., Anderson W., ZuWallack R. et al. Use of a long�acting inhaled β2�adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 163: 1087-1092Dahl R., Greefhorst L.A., Nowak D. et al. Inhaled for� moterol dry powder versus ipratropium bromide in chron� ic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 164: 778-784Dahl R., Greefhorst L.A., Nowak D. et al. Inhaled for� moterol dry powder versus ipratropium bromide in chron� ic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 164: 778-784Rossi A., Kristufek P., Levine B.E. et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow�release theophylline in the treatment of COPD. Chest 2002; 121: 1058-1069Rossi A., Kristufek P., Levine B.E. et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow�release theophylline in the treatment of COPD. Chest 2002; 121: 1058-1069Hogg J.C. Pathophysiology of airflow limitation in chron� ic obstructive pulmonary disease. Lancet 2004; 364: 709-721Hogg J.C. Pathophysiology of airflow limitation in chron� ic obstructive pulmonary disease. Lancet 2004; 364: 709-721Pauwels R.A., Lofdahl C.G., Laitinen L.A. et al. Long�term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society study on chronic obstructive pulmonary disease. N. Engl. J. Med. 1999; 340: 1948-1953Pauwels R.A., Lofdahl C.G., Laitinen L.A. et al. Long�term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society study on chronic obstructive pulmonary disease. N. Engl. J. Med. 1999; 340: 1948-1953Burge P.S., Calverley P.M., Jones P.W. et al. on behalf of the ISOLDE study investigators. Randomised, double blind, placebo controled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary dis� ease: the ISOLDE trial. Br. Med. J. 2000; 320: 1297-1303Burge P.S., Calverley P.M., Jones P.W. et al. on behalf of the ISOLDE study investigators. Randomised, double blind, placebo controled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary dis� ease: the ISOLDE trial. Br. Med. J. 2000; 320: 1297-1303Lung Health Study Research Group. Effect of inhaled tri� amcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N. Engl. J. Med. 2000; 343: 1902-1909Lung Health Study Research Group. Effect of inhaled tri� amcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N. Engl. J. Med. 2000; 343: 1902-1909Cazzola M., Dahl R. Inhaled combination therapy with long�acting β2�agonists and corticosteroids in stable COPD. Chest 2004; 126: 220-237Cazzola M., Dahl R. Inhaled combination therapy with long�acting β2�agonists and corticosteroids in stable COPD. Chest 2004; 126: 220-237Hanania N.A. The impact of inhaled corticosteroid and long�acting β�agonist combination therapy on outcomes in COPD. Pulmon. Pharmacol. Ther. 2008; 21: 540-550Hanania N.A. The impact of inhaled corticosteroid and long�acting β�agonist combination therapy on outcomes in COPD. Pulmon. Pharmacol. Ther. 2008; 21: 540-550Welte T. Optimising treatment for COPD - new strategies for combination therapy. Int. J. Clin. Pract. 2009; 63: 1136-1149Welte T. Optimising treatment for COPD - new strategies for combination therapy. Int. J. Clin. Pract. 2009; 63: 1136-1149Barnes P.J. Scientific rationale for inhaled combination therapy with long�acting beta2�agonists and corticos� teroids. Eur. Respir. J. 2002; 19: 182-191Barnes P.J. Scientific rationale for inhaled combination therapy with long�acting beta2�agonists and corticos� teroids. Eur. Respir. J. 2002; 19: 182-191Finney P.A., Donnelly L.E., Belvisi M.G. et al. Chronic sys� temic administration of salmeterol to rats promotes pul� monary beta(2)�adrenoceptor desensitization and down� regulation of G(s alpha). Br. J. Pharmacol. 2001; 132: 1261-1270Finney P.A., Donnelly L.E., Belvisi M.G. et al. Chronic sys� temic administration of salmeterol to rats promotes pul� monary beta(2)�adrenoceptor desensitization and down� regulation of G(s alpha). Br. J. Pharmacol. 2001; 132: 1261-1270Giembycz M.A., Kaur M., Leigh R., Newton R. A Holy Grail of asthma management: toward understanding how long�acting β2�adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids. Br. J. Pharmacol. 2008; 153: 1090-1104Giembycz M.A., Kaur M., Leigh R., Newton R. A Holy Grail of asthma management: toward understanding how long�acting β2�adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids. Br. J. Pharmacol. 2008; 153: 1090-1104Barnes P.J., Shapiro S.D., Pauwels R.A. Chronic obstruc� tive pulmonary disease: molecular and cellular mecha� nisms. Eur. Respir. J. 2003; 22: 672-688Barnes P.J., Shapiro S.D., Pauwels R.A. Chronic obstruc� tive pulmonary disease: molecular and cellular mecha� nisms. Eur. Respir. J. 2003; 22: 672-688Barnes P.J. Mediators of chronic obstructive pulmonary disease. Pharmacol. Rev. 2004; 56: 515-548Barnes P.J. Mediators of chronic obstructive pulmonary disease. Pharmacol. Rev. 2004; 56: 515-548Barnes P.J. Macrophages as orchestrators of COPD. J. COPD 2004; 1: 59-70Barnes P.J. Macrophages as orchestrators of COPD. J. COPD 2004; 1: 59-70Burgel P.R., Nadel J.A. Roles of epidermal growth factor receptor activation in epithelial cell repair and mucin pro� duction in airway epithelium. Thorax 2004; 59: 992-996Burgel P.R., Nadel J.A. Roles of epidermal growth factor receptor activation in epithelial cell repair and mucin pro� duction in airway epithelium. Thorax 2004; 59: 992-996Saetta M., Turato G., Maestrelli P. et al. Cellular and struc� tural bases of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 163: 1304-1309Saetta M., Turato G., Maestrelli P. et al. Cellular and struc� tural bases of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 163: 1304-1309Gan W.Q., Man S.F., Senthilselvan A., Sin D.D. Associa� tion between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta� analysis. Thorax 2004; 59: 574-580Gan W.Q., Man S.F., Senthilselvan A., Sin D.D. Associa� tion between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta� analysis. Thorax 2004; 59: 574-580Agusti A.G., Noguera A., Sauleda J. et al. Systemic effects of chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21: 347-360Agusti A.G., Noguera A., Sauleda J. et al. Systemic effects of chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21: 347-360Wouters E.F., Creutzberg E.C., Schols A.M. Systemic effects in COPD. Chest 2002; 121 (Suppl. 5): 127S-130SWouters E.F., Creutzberg E.C., Schols A.M. Systemic effects in COPD. Chest 2002; 121 (Suppl. 5): 127S-130SKeatings V.M., Jatakanon A., Worsdell Y.M. et al. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am. J. Respir. Crit. Care Med. 1997; 155: 542-548Keatings V.M., Jatakanon A., Worsdell Y.M. et al. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am. J. Respir. Crit. Care Med. 1997; 155: 542-548Culpitt S.V., Maziak W., Loukidis S. et al. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 160: 1635-1639Culpitt S.V., Maziak W., Loukidis S. et al. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 160: 1635-1639Gan W.Q., Man S.F., Sin D.D. Effects of inhaled corticos� teroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta�analy� sis. BMC Pulm. Med. 2005; 5: 3Gan W.Q., Man S.F., Sin D.D. Effects of inhaled corticos� teroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta�analy� sis. BMC Pulm. Med. 2005; 5: 3Hattotuwa K.L., Gizycki M.J., Ansari T.W. et al. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double�blind, placebo� controlled biopsy study. Am. J. Respir. Crit. Care Med. 2002; 165: 1592-1596Hattotuwa K.L., Gizycki M.J., Ansari T.W. et al. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double�blind, placebo� controlled biopsy study. Am. J. Respir. Crit. Care Med. 2002; 165: 1592-1596Bourbeau J., Christodoulopoulos P., Maltais F. et al. Effect of salmeterol / fluticasone propionate on airway inflam� mation in COPD: a randomised controlled trial. Thorax 2007; 62: 938-943Bourbeau J., Christodoulopoulos P., Maltais F. et al. Effect of salmeterol / fluticasone propionate on airway inflam� mation in COPD: a randomised controlled trial. Thorax 2007; 62: 938-943Lapperre T.S., SnoeckStroband J.B., Gosman M.M. et al. Effect of fluticasone with and without salmeterol on pul� monary outcomes in chronic obstructive pulmonary dis� ease: a randomized trial. Ann. Intern. Med. 2009; 151: 517-527Lapperre T.S., SnoeckStroband J.B., Gosman M.M. et al. Effect of fluticasone with and without salmeterol on pul� monary outcomes in chronic obstructive pulmonary dis� ease: a randomized trial. Ann. Intern. Med. 2009; 151: 517-527Barnes N.C., Qiu Y.S., Pavord I.D. et al. Antiinflamma� tory effects of salmeterol / fluticasone propionate in chronic obstructive lung disease. Am. J. Respir. Crit. Care Med. 2006; 173: 736-743Barnes N.C., Qiu Y.S., Pavord I.D. et al. Antiinflamma� tory effects of salmeterol / fluticasone propionate in chronic obstructive lung disease. Am. J. Respir. Crit. Care Med. 2006; 173: 736-743Barnes P.J., Adcock I.M., Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur. Respir. J. 2005; 25: 552-563Barnes P.J., Adcock I.M., Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur. Respir. J. 2005; 25: 552-563Ito K., Ito M., Elliott W.M. et al. Decreased histone deacetylase activity in chronic obstructive pulmonary dis� ease. N. Engl. J. Med. 2005; 352: 1967-1976Ito K., Ito M., Elliott W.M. et al. Decreased histone deacetylase activity in chronic obstructive pulmonary dis� ease. N. Engl. J. Med. 2005; 352: 1967-1976Sin D.D., Lacy P., York E., Man S.F. Effects of fluticasone on systemic markers of inflammation in chronic obstruc� tive pulmonary disease. Am. J. Respir. Crit. Care Med. 2004; 170: 760-765Sin D.D., Lacy P., York E., Man S.F. Effects of fluticasone on systemic markers of inflammation in chronic obstruc� tive pulmonary disease. Am. J. Respir. Crit. Care Med. 2004; 170: 760-765Sin D.D., Man S.F., Marciniuk D.D. et al. The effects of fluticasone with or without salmeterol on systemic bio� markers of inflammation in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2008; 177: 1207-1214Sin D.D., Man S.F., Marciniuk D.D. et al. The effects of fluticasone with or without salmeterol on systemic bio� markers of inflammation in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2008; 177: 1207-1214Man P.S.F., Zhang X., Vessey R. et al. The effects of inhaled and oral corticosteroids on serum inflammatory biomark� ers in COPD: an exploratory study. Ther. Adv. Respir. Dis. 2009; 3: 73-80Man P.S.F., Zhang X., Vessey R. et al. The effects of inhaled and oral corticosteroids on serum inflammatory biomark� ers in COPD: an exploratory study. Ther. Adv. Respir. Dis. 2009; 3: 73-80Huiart L., Ernst P., Ranouil X., Suissa S. Low�dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD. Eur. Respir. J. 2005; 25: 634-639Huiart L., Ernst P., Ranouil X., Suissa S. Low�dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD. Eur. Respir. J. 2005; 25: 634-639Macie C., Wooldrage K., Manfred J. et al. Inhaled corticos� teroids and mortality in COPD. Proc. Am. Thorac. Soc. 2005; 2: A91Macie C., Wooldrage K., Manfred J. et al. Inhaled corticos� teroids and mortality in COPD. Proc. Am. Thorac. Soc. 2005; 2: A91Sin D.D., Wu L., Anderson J.A. et al. Inhaled corticos� teroids and mortality in chronic obstructive pulmonary disease. Thorax 2005; 60: 992-997Sin D.D., Wu L., Anderson J.A. et al. Inhaled corticos� teroids and mortality in chronic obstructive pulmonary disease. Thorax 2005; 60: 992-997Lofdahl C.G., Postma D.S., Pride N.B. et al. Possible pro� tection by inhaled budesonide against ischaemic cardiac events in mild COPD. Eur. Respir. J. 2007; 29: 1115-1159Lofdahl C.G., Postma D.S., Pride N.B. et al. Possible pro� tection by inhaled budesonide against ischaemic cardiac events in mild COPD. Eur. Respir. J. 2007; 29: 1115-1159Loke Y.K., Kwok C.S., Singh S. Risk of myocardial infarc� tion and cardiovascular death associated with inhaled cor� ticosteroids in COPD: a systematic review and meta� analysis. Eur. Respir. J. 2010; 35: 1003-1021Loke Y.K., Kwok C.S., Singh S. Risk of myocardial infarc� tion and cardiovascular death associated with inhaled cor� ticosteroids in COPD: a systematic review and meta� analysis. Eur. Respir. J. 2010; 35: 1003-1021Kiri V.A., Fabbri L.M., Davis K.J., Soriano J.B. Inhaled corticosteroids and risk of lung cancer among COPD patients who quit smoking. Respir. Med. 2009; 103: 85-90Kiri V.A., Fabbri L.M., Davis K.J., Soriano J.B. Inhaled corticosteroids and risk of lung cancer among COPD patients who quit smoking. Respir. Med. 2009; 103: 85-90Vestbo J., Sorensen T., Lange P. et al. Long�term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353: 1819-1823Vestbo J., Sorensen T., Lange P. et al. Long�term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353: 1819-1823van der Valk P., Monninkhof E., van der Palen J. et al. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am. J. Respir. Crit. Care Med. 2002; 166: 1358-1363van der Valk P., Monninkhof E., van der Palen J. et al. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am. J. Respir. Crit. Care Med. 2002; 166: 1358-1363Wouters E.F., Postma D.S., Fokkens B. et al. Withdrawal of fluticasone propionate from combined salmeterol / fluti� casone treatment in patients with COPD causes immedi� ate and sustained disease deterioration: a randomised con� trolled trial. Thorax 2005; 60: 480-487Wouters E.F., Postma D.S., Fokkens B. et al. Withdrawal of fluticasone propionate from combined salmeterol / fluti� casone treatment in patients with COPD causes immedi� ate and sustained disease deterioration: a randomised con� trolled trial. Thorax 2005; 60: 480-487Calverley P.M., Anderson J.A., Celli B. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356: 775-789Calverley P.M., Anderson J.A., Celli B. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356: 775-789Calverley P., Pauwels R., Vestbo J. et al. Combined salme� terol and fluticasone in the treatment of COPD: a ran� domised controlled trial. Lancet 2003; 361 (9356): 449-456Calverley P., Pauwels R., Vestbo J. et al. Combined salme� terol and fluticasone in the treatment of COPD: a ran� domised controlled trial. Lancet 2003; 361 (9356): 449-456Suissa S., Barnes P.J. Inhaled corticosteroids in COPD: the case against. Eur. Respir. J. 2009; 34: 13-16Suissa S., Barnes P.J. Inhaled corticosteroids in COPD: the case against. Eur. Respir. J. 2009; 34: 13-16Postma D.S., Calverley P. Inhaled corticosteroids in COPD - a case in favour. Eur. Respir. J. 2009; 34: 10-12Postma D.S., Calverley P. Inhaled corticosteroids in COPD - a case in favour. Eur. Respir. J. 2009; 34: 10-12Celli B.R., Thomas N.E., Anderson J.A. et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am. J. Respir. Crit. Care Med. 2008; 178: 332-338Celli B.R., Thomas N.E., Anderson J.A. et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am. J. Respir. Crit. Care Med. 2008; 178: 332-338Szafranski W., Cukier A., Ramirez A. et al. Efficacy and safety of budesonide / formoterol in the management of chronic obstructive disease. Eur. Respir. J. 2003; 21: 74-81Szafranski W., Cukier A., Ramirez A. et al. Efficacy and safety of budesonide / formoterol in the management of chronic obstructive disease. Eur. Respir. J. 2003; 21: 74-81Calverley P.M., Boonsawat W., Cseke Z. et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 22: 912-919Calverley P.M., Boonsawat W., Cseke Z. et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 22: 912-919Halpin D.M.G. Evaluating the effectiveness of combina� tion therapy to prevent COPD exacerbations: the value of NNT analysis. Int. J. Clin. Pract. 2005; 59: 1187-1194Halpin D.M.G. Evaluating the effectiveness of combina� tion therapy to prevent COPD exacerbations: the value of NNT analysis. Int. J. Clin. Pract. 2005; 59: 1187-1194Aaron S.D., Vandemheen K.L., Fergusson D. et al. Tio� tropium in combination with placebo, salmeterol, or fluti� casone�salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med. 2007; 146: 545-555Aaron S.D., Vandemheen K.L., Fergusson D. et al. Tio� tropium in combination with placebo, salmeterol, or fluti� casone�salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med. 2007; 146: 545-555Schermer T., Chavannes N., Dekhuijzen R. et al. Fluti� casone and N�acetylcysteine in primary care patients with COPD or chronic bronchitis. Respir. Med. 2009; 103: 542-551Schermer T., Chavannes N., Dekhuijzen R. et al. Fluti� casone and N�acetylcysteine in primary care patients with COPD or chronic bronchitis. Respir. Med. 2009; 103: 542-551de Melo M.N., Ernst P., Suissa S. Inhaled corticosteroids and the risk of a first exacerbation in COPD patients. Eur. Respir. J. 2004; 23: 692-697de Melo M.N., Ernst P., Suissa S. Inhaled corticosteroids and the risk of a first exacerbation in COPD patients. Eur. Respir. J. 2004; 23: 692-697Agarwal R., Aggarwal A.N., Gupta D, Jindal S.K. Inhaled corticosteroids vs placebo for preventing COPD exacerba� tions. A systematic review and metaregression of random� ized controlled trials. Chest 2010; 137; 318-325Agarwal R., Aggarwal A.N., Gupta D, Jindal S.K. Inhaled corticosteroids vs placebo for preventing COPD exacerba� tions. A systematic review and metaregression of random� ized controlled trials. Chest 2010; 137; 318-325Cyr M.C., Beauchesne M.F., Lemière C. et al. Effects of inhaled corticosteroids in monotherapy or combined with long�acting β2�agonists on mortality among patients with chronic obstructive pulmonary disease. Ann. Pharmaco� therapy 2010; 44: 613-622Cyr M.C., Beauchesne M.F., Lemière C. et al. Effects of inhaled corticosteroids in monotherapy or combined with long�acting β2�agonists on mortality among patients with chronic obstructive pulmonary disease. Ann. Pharmaco� therapy 2010; 44: 613-622Kliber A., Lynd L.D., Sin D.D. The effects of long�acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease. Respir. Res. 2010; 11: 56Kliber A., Lynd L.D., Sin D.D. The effects of long�acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease. Respir. Res. 2010; 11: 56Sin D.D., McAlister F.A., Man S.F., Anthonisen N.R. Con� temporary management of chronic obstructive pulmonary disease: scientific review. J.A.M.A. 2003; 290: 2301-2312Sin D.D., McAlister F.A., Man S.F., Anthonisen N.R. Con� temporary management of chronic obstructive pulmonary disease: scientific review. J.A.M.A. 2003; 290: 2301-2312Suissa S., Ernst P., Vandemheen K.L. et al. Methodological issues in therapeutic trials of COPD. Eur. Respir. J. 2008; 31: 927-933Suissa S., Ernst P., Vandemheen K.L. et al. Methodological issues in therapeutic trials of COPD. Eur. Respir. J. 2008; 31: 927-933Suissa S. Lung function decline in COPD trials: bias from regression to the mean. Eur. Respir. J. 2008; 32: 829-831Suissa S. Lung function decline in COPD trials: bias from regression to the mean. Eur. Respir. J. 2008; 32: 829-831La Vecchia C., Fabbri L.M. Prevention of death in COPD. N. Engl. J. Med. 2007; 356: 2211-2212La Vecchia C., Fabbri L.M. Prevention of death in COPD. N. Engl. J. Med. 2007; 356: 2211-2212Brightling C.E., Monteiro W., Ward R. et al. Sputum eosinophilia and short�term response to prednisolone in chronic obstructive pulmonary disease: a randomised con� trolled trial. Lancet 2000; 356: 1480-1485Brightling C.E., Monteiro W., Ward R. et al. Sputum eosinophilia and short�term response to prednisolone in chronic obstructive pulmonary disease: a randomised con� trolled trial. Lancet 2000; 356: 1480-1485Kerstjens H.A.M., Brand P.L.P., Hughes M.D. et al. A com� parison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. N. Engl. J. Med. 1992; 327: 1413-1419Kerstjens H.A.M., Brand P.L.P., Hughes M.D. et al. A com� parison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. N. Engl. J. Med. 1992; 327: 1413-1419Kerstjens H.A.M., Overbeek S.E., Schouten J.P. et al. Airways hyperresponsiveness, bronchodilator response, allergy and smoking predict improvement in FEV1 during long�term inhaled corticosteroid treatment. Eur. Respir. J. 1993; 6: 868-876Kerstjens H.A.M., Overbeek S.E., Schouten J.P. et al. Airways hyperresponsiveness, bronchodilator response, allergy and smoking predict improvement in FEV1 during long�term inhaled corticosteroid treatment. Eur. Respir. J. 1993; 6: 868-876Verhoeven G.T., Hegmans J.P., Mulder P.G. et al. Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness. Thorax 2002; 57: 694-700Verhoeven G.T., Hegmans J.P., Mulder P.G. et al. Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness. Thorax 2002; 57: 694-700Leuppi J.D., Tandjung R., Anderson S.D. et al. Prediction of treatment�response to inhaled corticosteroids by manni� tol�challenge test in COPD. A proof of concept. Pulm. Pharmacol. Ther. 2005; 18: 83-88Leuppi J.D., Tandjung R., Anderson S.D. et al. Prediction of treatment�response to inhaled corticosteroids by manni� tol�challenge test in COPD. A proof of concept. Pulm. Pharmacol. Ther. 2005; 18: 83-88Leigh R., Pizzichini M.M.M., Morris M.M. et al. Stable COPD: predicting benefit from high�dose inhaled corti� costeroid treatment. Eur. Respir. J. 2006; 27: 964-971Leigh R., Pizzichini M.M.M., Morris M.M. et al. Stable COPD: predicting benefit from high�dose inhaled corti� costeroid treatment. Eur. Respir. J. 2006; 27: 964-971Brightling C.E., McKenna S., Hargadon B. et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 2005; 60: 193-198Brightling C.E., McKenna S., Hargadon B. et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 2005; 60: 193-198Lehtimaki L., Kankaanranta H., Saarelainen S. et al. Bronchial nitric oxide is related to symptom relief during fluticasone treatment in COPD. Eur. Respir. J. 2010; 35: 72-78Lehtimaki L., Kankaanranta H., Saarelainen S. et al. Bronchial nitric oxide is related to symptom relief during fluticasone treatment in COPD. Eur. Respir. J. 2010; 35: 72-78Tashkin D.P., Murray H.E., Skeans M. et al. Skin manifes� tations of inhaled corticosteroids in COPD patients. Results from Lung Health Study II. Chest 2004; 126: 1123-1133Tashkin D.P., Murray H.E., Skeans M. et al. Skin manifes� tations of inhaled corticosteroids in COPD patients. Results from Lung Health Study II. Chest 2004; 126: 1123-1133Etminan M., Sadatsafavi M., Ganjizade Zavareh S. et al. Inhaled corticosteroids and the risk of fractures in older adults: a systematic review and meta�analysis. Drug. Saf. 2008; 31: 409-414Etminan M., Sadatsafavi M., Ganjizade Zavareh S. et al. Inhaled corticosteroids and the risk of fractures in older adults: a systematic review and meta�analysis. Drug. Saf. 2008; 31: 409-414Hubbard R.F., Tattersfield A.F., Smith C.F. et al. Use of inhaled corticosteroids and the risk of fracture. Chest 2006; 130: 1687-1688Hubbard R.F., Tattersfield A.F., Smith C.F. et al. Use of inhaled corticosteroids and the risk of fracture. Chest 2006; 130: 1687-1688Hubbard R.B., Smith C.J., Smeeth L. et al. Inhaled corti� costeroids and hip fracture: a population�based case�con� trol study. Am. J. Respir. Crit. Care Med. 2002; 166: 1563-1566Hubbard R.B., Smith C.J., Smeeth L. et al. Inhaled corti� costeroids and hip fracture: a population�based case�con� trol study. Am. J. Respir. Crit. Care Med. 2002; 166: 1563-1566Lee T.A., Weiss K.B. Fracture risk associated with inhaled corticosteroid use in COPD. Am. J. Respir. Crit. Care Med. 2004; 169: 855-859Lee T.A., Weiss K.B. Fracture risk associated with inhaled corticosteroid use in COPD. Am. J. Respir. Crit. Care Med. 2004; 169: 855-859Vestergaard P., Rejnmark L., Mosekilde L. Fracture risk in patients with chronic lung diseases treated with bron� chodilator drugs and inhaled and oral corticosteroids. Chest 2007; 13: 1599-1560Vestergaard P., Rejnmark L., Mosekilde L. Fracture risk in patients with chronic lung diseases treated with bron� chodilator drugs and inhaled and oral corticosteroids. Chest 2007; 13: 1599-1560Israel E., Banerjee T.R., Fitzmaurice G.M. et al. Effects of inhaled glucocorticoids on bone density in premenopausal women. N. Engl. J. Med. 2001; 345: 941-947Israel E., Banerjee T.R., Fitzmaurice G.M. et al. Effects of inhaled glucocorticoids on bone density in premenopausal women. N. Engl. J. Med. 2001; 345: 941-947Ferguson G.T., Calverley P.M., Anderson J.A. et al. Prevalence and progression of osteoporosis in patients with COPD: results from the towards a revolution in COPD health study. Chest 2009; 136: 1456-1465Ferguson G.T., Calverley P.M., Anderson J.A. et al. Prevalence and progression of osteoporosis in patients with COPD: results from the towards a revolution in COPD health study. Chest 2009; 136: 1456-1465Weatherall M., Clay J., James K. et al. Dose�response rela� tionship of inhaled corticosteroids and cataracts: a systemat� ic review and meta�analysis. Respirology 2009; 14: 983-990Weatherall M., Clay J., James K. et al. Dose�response rela� tionship of inhaled corticosteroids and cataracts: a systemat� ic review and meta�analysis. Respirology 2009; 14: 983-990Uboweja A., Malhotra S., Pandhi P. Effect of inhaled corti� costeroids on risk of development of cataract: a meta� analysis development of cataract: a meta�analysis. Fundam. Clin. Pharmacol. 2006; 20: 305-309Uboweja A., Malhotra S., Pandhi P. Effect of inhaled corti� costeroids on risk of development of cataract: a meta� analysis development of cataract: a meta�analysis. Fundam. Clin. Pharmacol. 2006; 20: 305-309Gonzalez A.V., Li G., Suissa S., Ernst P. Risk of glaucoma in elderly patients treated with inhaled corticosteroids for chronic airflow obstruction. Pulm. Pharmacol. Ther. 2010; 23: 65-70Gonzalez A.V., Li G., Suissa S., Ernst P. Risk of glaucoma in elderly patients treated with inhaled corticosteroids for chronic airflow obstruction. Pulm. Pharmacol. Ther. 2010; 23: 65-70Suissa S., Kezouh A., Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am. J. Med. 2010; 123: 1001-1006Suissa S., Kezouh A., Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am. J. Med. 2010; 123: 1001-1006Kardos P., Wencker M., Glaab T., Vogelmeier C. Impact of salmeterol / fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary dis� ease. Am. J. Respir. Crit. Care Med. 2007; 175: 144-149Kardos P., Wencker M., Glaab T., Vogelmeier C. Impact of salmeterol / fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary dis� ease. Am. J. Respir. Crit. Care Med. 2007; 175: 144-149Wedzicha J.A., Calverley P.M.A., Seemungal T.A. et al. The prevention of chronic obstructive pulmonary disease exacer� bations by salmeterol / fluticasone propionate or tiotropium bromide. Am. J. Respir. Crit. Care Med. 2008; 177: 19-26Wedzicha J.A., Calverley P.M.A., Seemungal T.A. et al. The prevention of chronic obstructive pulmonary disease exacer� bations by salmeterol / fluticasone propionate or tiotropium bromide. Am. J. Respir. Crit. Care Med. 2008; 177: 19-26Anzueto A., Ferguson G.T., Feldman G. et al. Effect of fluti� casone propionate / salmeterol (250 / 50) on COPD exac� erbations and impact on patient outcomes. COPD 2009; 6: 320-329Anzueto A., Ferguson G.T., Feldman G. et al. Effect of fluti� casone propionate / salmeterol (250 / 50) on COPD exac� erbations and impact on patient outcomes. COPD 2009; 6: 320-329Ernst P., Gonzalez A.V., Brassard P. et al. Inhaled corticos� teroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am. J. Respir. Crit. Care Med. 2007; 176: 162-166Ernst P., Gonzalez A.V., Brassard P. et al. Inhaled corticos� teroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am. J. Respir. Crit. Care Med. 2007; 176: 162-166Авдеев С.Н., Баймаканова Г.Е. Ингаляционные глюко� кортикостероиды и риск развития пневмонии у боль� ных хронической обструктивной болезнью легких. Пульмонология 2010; 5: 101-109Авдеев С.Н., Баймаканова Г.Е. Ингаляционные глюко� кортикостероиды и риск развития пневмонии у боль� ных хронической обструктивной болезнью легких. Пульмонология 2010; 5: 101-109Lapperre T.S. Airway pathology in COPD: smoking cessa� tion and pharmacological treatment intervention. Results from the GLUCOLD study. D.Sc. Thesis. Printed by: Pasmans Offsetdrukkerij B.V., Den Haag. 2009: 1-167Lapperre T.S. Airway pathology in COPD: smoking cessa� tion and pharmacological treatment intervention. Results from the GLUCOLD study. D.Sc. Thesis. Printed by: Pasmans Offsetdrukkerij B.V., Den Haag. 2009: 1-167Grashoff W.F., Sont J.K., Sterk P.J. et al. Chronic obstruc� tive pulmonary disease: role of bronchiolar mast cells and macrophages. Am. J. Pathol. 1997; 151: 1785-1790Grashoff W.F., Sont J.K., Sterk P.J. et al. Chronic obstruc� tive pulmonary disease: role of bronchiolar mast cells and macrophages. Am. J. Pathol. 1997; 151: 1785-1790John M., Bosse S., Oltmanns U. et al. Effects of inhaled HFA beclomethasone on pulmonary function and symp� toms in patients with chronic obstructive pulmonary dis� ease. Respir. Med. 2005; 99: 1418-1424John M., Bosse S., Oltmanns U. et al. Effects of inhaled HFA beclomethasone on pulmonary function and symp� toms in patients with chronic obstructive pulmonary dis� ease. Respir. Med. 2005; 99: 1418-1424Calverley P.M., Kuna P., Monsó E. et al. Beclomethasone / formoterol in the management of COPD: A randomised controlled trial. Respir. Med. 2010; 104: 1858-1868Calverley P.M., Kuna P., Monsó E. et al. Beclomethasone / formoterol in the management of COPD: A randomised controlled trial. Respir. Med. 2010; 104: 1858-1868Drummond M.B., Dasenbrook E.C., Pitz M.W. et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta�analysis. J.A.M.A. 2008; 300: 2407-2416Drummond M.B., Dasenbrook E.C., Pitz M.W. et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta�analysis. J.A.M.A. 2008; 300: 2407-2416
The authors declare that there are no conflicts of interest present.